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Abstract 
Introduction 
Previous studies have identified common germline variants nominally associated with breast 
cancer survival. These associations have not been widely replicated in further studies. The 
purpose of this study was to evaluate the association of previously reported SNPs with breast 
cancer specific survival using data from a pooled analysis of eight breast cancer survival 
genome-wide association studies (GWAS) from the Breast Cancer Association Consortium. 
Methods 
A literature review was conducted of all previously published associations between common 
germline variants and three survival outcomes: breast cancer specific survival, overall 
survival and disease-free survival. All associations which reached the nominal significance 
level of p-value < 0.05 were included. Single nucleotide polymorphisms that had been 
previously reported as nominally associated with at least one survival outcome were 
evaluated in the pooled analysis of over 37,000 breast cancer cases for association with breast 
cancer specific survival. Previous associations were evaluated using a one-sided test based on 
the reported direction of effect. 
Results 
Fifty-six variants from 45 previous publications were evaluated in the meta-analysis. Fifty-
four of these were evaluated in the full set of 37,954 breast cancer cases with 2,900 events 
and the two additional variants were evaluated in a reduced sample size of 30,000 samples in 
order to ensure independence from the previously published studies. Five variants reached 
nominal significance (p < 0.05) in the pooled GWAS data compared to 2.8 expected under 
the null hypothesis. Seven additional variants were associated (p < 0.05) with ER positive 
disease. 
Conclusions 
Although no variants reached genome-wide significance (p < 5 x 10−8), these results suggest 
that there is some evidence of association between candidate common germline variants and 
breast cancer prognosis. Larger studies from multi-national collaborations are necessary to 
increase the power to detect associations, between common variants and prognosis, at more 
stringent significance levels. 
Introduction 
Breast cancer is the most commonly diagnosed cancer in women, in the world, with an 
estimated 1.67 million new cancer cases diagnosed in 2012. Breast cancer mortality is the 
second most common cancer-related death in women in the more developed regions of the 
world and accounts for 15.4% of cancer related deaths in women [1]. Breast cancer outcome 
is affected by several factors including: age, tumour size, tumour grade, extent of local and 
distal spread at diagnosis, ER status, HER2 status and treatment received. It is also likely that 
inherited host characteristics, such as genetic variants, are important [2]. 
The association between common germline genetic variation and breast cancer survival has 
been examined in many candidate gene studies investigating genes in pathways known to be 
involved in breast cancer [3]. These studies have identified numerous single nucleotide 
polymorphisms (SNPs) associated with outcome at nominal significance levels, but none 
have been widely replicated in further studies. The exceptions to this are three genome-wide 
association studies [4-6] and a study from the Breast Cancer Association Consortium 
(BCAC), which had substantial power to detect associated variants with large effect sizes 
(HR > 2) [7]. Two of those genome-wide association studies have reported significant 
associations for three polymorphisms (rs9934948, rs3784099, rs4778137) [4,6]. The aim of 
this study was to evaluate the association of previously reported SNPs with prognosis using 
data from a hypothesis-generating pooled analysis of eight breast cancer survival GWAS 
from ten studies including 37,954 breast cancer cases [Guo, Schmidt, Pharoah et al., in press]. 
  
Methods 
Literature review 
Studies reporting common polymorphisms associated with breast cancer prognosis were 
identified by searching both Google Scholar and Pubmed. We searched Google Scholar using 
the search terms: “breast cancer”, “survival”, “prognosis”, “polymorphisms” and “SNPs”. 
The search terms for Pubmed were “breast cancer” AND (“survival” OR “prognosis”) AND 
(“polymorphism” OR “SNP”). The references of all identified studies were then individually 
interrogated for any additional studies. The search was last updated on 6th June 2014. We 
considered studies to be eligible for inclusion if they reported an association between a 
germline genetic variant and at least one of the following end-points: overall survival, 
disease-free survival and breast cancer specific survival. Studies evaluating the prognostic 
importance of rare high penetrance variants with minor allele frequency < 2% in BRCA1, 
BRCA2 and CHEK2 were omitted from the review. Only one study conducted ER subtype 
specific analyses. 
For the purposes of comparison, all studies that used genetic models that grouped together 
two genotypes into a single category were defined as using 'dominance models'. This 
category includes both dominant and recessive models as each study's definition of a 
dominant or recessive model is dependent on which allele is the major or minor allele, 
whether they consider the effect allele to be bi-directional, or whether they focus on only the 
risk allele. 
Genome-wide association studies 
We used data from a combined analysis of eight breast cancer GWAS, from ten studies [8-
18], that had genotype data from a genome-wide SNP array and had collected follow-up time 
data for the 37,954 breast cancer cases [Guo, Schmidt, Pharoah et al., in press]. Genotype and 
sample quality control were carried out separately for each study. In short, SNPs were 
excluded based on: low call rate, minor allele frequency < 1% and significant deviation of 
genotype frequencies from Hardy-Weinberg equilibrium. Samples were excluded for: low 
call rate, ambiguous gender, relatedness and extreme heterozygosity. We also excluded 
subjects of less than 90% European ancestry. Sample ancestry was determined separately for 
each GWAS included in the meta-analysis using either principal component analysis, multi-
dimensional scaling or LAMP based on ethnicities from HapMap samples. Samples with less 
than 90% European ancestry were excluded. As different genotyping arrays had been used for 
the different studies imputation had been performed using a reference panel from the 1000 
Genomes Project [19] [Guo,Schmidt,Pharoah et al., in press]. We utilised the imputed data 
for the SNPs of interest in this study. Details of the pooled studies are shown in Additional 
files 1 and 2. 
Cox proportional hazards models were fitted to assess the association of genotype with breast 
cancer specific mortality under a co-dominant (log-additive) genetic model using the 
likelihood ratio test. The models were adjusted for principal components in order to minimise 
the effect of population sub-structure, and the COGS (Collaborative Oncological Gene-
environment Study) [15] dataset was stratified by study. Each survival GWAS was analysed 
separately and the results were harmonized and combined using a standard inverse-variance 
weighted fixed effects meta-analysis. In order to compare the results with the published 
associations we used a one-sided test based on the reported direction of effect. In the initial 
analysis for all 56 SNPs models were unadjusted for prognostic factors. However, we 
conducted multivariable analysis of the previously reported SNPs that were significantly 
associated with survival adjusting for age, stage and grade using 29,360 samples from the 
COGS study. 
Results 
Literature review 
We identified 46 publications reporting nominally significant associations between 62 
germline variants and survival after a breast cancer diagnosis. Details of each variant and the 
reported association with breast cancer prognosis are shown in Additional file 3. The median 
sample size was 890 cases, the smallest study had 85 cases and the largest 25,853. Fifty-nine 
variants were from 44 candidate gene studies and three variants were identified through 
GWAS. The candidate genes were involved in the following pathways: DNA repair, cell 
cycle control, matrix metalloproteinases, immune response, drug response, tumour-
progression, vitamin D receptors and miscellaneous other pathways (Table 1). Findings from 
the identified publications were infrequently replicated; only six variants out of the 62 were 
reported in at least one subsequent publication. 
Table 1 Previously identified breast cancer survival genes in cancer related pathways 
Pathway Nearest Gene References
DNA Repair XRCC1, XRCC2, XRCC3, RAD51B, LIG4, ERCC2 [6,27-31] 
Cell Cycle Control CCND1, CCND3, PRKAG2, TP53, SIPA1, FGFR2, PPP2R2B [27,32-38] 
Matrix Metalloproteinases MMP7, MMP8, MMP2, SERPINE1, TIMP-3 [22,39-43] 
Immune and Drug response, 
metabolism 
Il-10, IL-6, IL-21, MPO, GSTP1, COMT, CYP19A1, CYP1A1, 
SULT1E1, NEF2L2, TLR4, SLC28A3, CD24, CD44, NQO1 
[13,21,23,44-56] 
Tumour-progression NOS3, VEGF, NME1, SELE, GNAS1, ZFP36, TGF [57-63] 
Vitamin D Receptors RXRA, VDR [64,65] 
Miscellaneous TOX3, MTHFR, COX11, OCA2, PLAUR. [4,7,33,64,66] 
NB – the genes mentioned here are the candidate genes listed in the previous publications or are the nearest gene 
to the SNP and are not necessarily the genes that the SNPs have a functional effect on. 
Meta-analysis findings 
Results from the GWAS meta-analysis included 58 of the 62 previously identified variants 
discussed above. The SNP (rs2886162) was replaced by a perfectly correlated tagSNP 
(rs2364725, r2 = 1). Associations for four of the variants identified: rs4778137 in OCA2, 
rs3803662 in TOX3, rs1042522 in TP53 and rs2479717 in CCND1 were discovered in studies 
carried out by the Breast Cancer Association Consortium using sets of samples included in 
our GWAS meta-analysis. Therefore, we are unable to replicate these associations 
independently in the full dataset. The substantial sample overlap between the studies that 
identified associations with rs4778137 and rs3803662 means that there is little to be gained 
by attempting to replicate their associations in the additional samples included in the meta-
analysis. However, the sample sizes in the studies identifying rs1042522 and rs2479717 were 
relatively small so we evaluated their association with breast cancer specific survival in the 
GWAS meta-analysis omitting the samples from studies used in the original publications. 
The two SNPs were evaluated in 29,224 and 31,434 samples respectively. 
The results for the 56 SNPs evaluated in the meta-analysis are presented in Additional file 4. 
In the analysis of all cases, five SNPs (rs2981582, rs1800566, rs9934948, rs1800470 and 
rs3775775) were significant with one-sided p-value < 0.05, 51 SNPs were not significant at 
this nominal p-value. The most significant association was for rs2981582 in FGFR2 (per G 
allele HR 1.09, 90% CI 1.04-1.14, one-sided p-value = 0.00085). All significantly associated 
SNPs had good imputation quality (r2 = 0.9-1). The imputation r2 for all 56 SNPs can be 
found in Additional file 4. No single SNP reached the stringent level of significance generally 
regarded as genome-wide significant (p-value < 5x10−8) but the number of moderately 
significant associations (5) was somewhat greater than that expected by chance (2.8). This is 
illustrated by the quantile-quantile plot shown in Figure 1. Seven SNPs not significantly 
associated with prognosis in all patients were significant in ER-positive disease. We found 
evidence of ER-positive specific associations with prognosis for 7 out of the 12 SNPs 
nominally associated (p < 0.05) with survival. These SNPs were not previously identified in 
patients with specifically ER positive disease however, our observations may agree with the 
previously reported results as most breast cancers are ER positive. We measured the level of 
heterogeneity between the studies included in the pooled analysis for the 12 SNPs associated 
with survival. There was moderate evidence of heterogeneity for the SNP rs2981582 (I2 = 
41.1%, p-value = 0.084). For all other SNPs there was low heterogeneity (I2 < 25%, p-value > 
0.2). Details of the SNPs nominally associated with breast cancer specific survival are shown 
in Table 2. The results for the nominally associated SNPs adjusted for age, stage and grade 
are shown in Additional file 5. The hazard ratios for some of the SNPs were attenuated after 
adjustment. Also, the associations with breast cancer specific survival of SNPs rs3775775 
and rs2333227 were stronger in the multivariable analysis. 
Figure 1 Quantile-quantile plot of results from look-up of previously reported associations in 
GWAS. Tests were one-sided with direction assumed from previous association. 
Table 2 Previously reported associations replicated in the meta-analysis 
      All cases ER negative cases ER positive cases
SNP Gene Published Model Effect Allele Effect Allele Freq HR (90% CI) One-sided 
p-value
HR (90% CI) One-sided 
p-value
HR (90% CI) One-sided  
p-value 
rs2981582 FGFR2 Bayraktar et al. [33] Dominance G 0.57 1.09 (1.04-1.14) 0.00085 1.08 (1.00-1.16) 0.052 1.04 (0.98-1.10) 0.15 
rs1800566 NQO1 Fagerholm et al. [13] Dominance A 0.19 1.10 (1.03-1.17) 0.0046 1.14 (1.03-1.25) 0.015 1.04 (0.95-1.13) 0.23
rs9934948 LOC100506172 Shu et al. [6] (GWAS) Co-dominance T 0.15 0.92 (0.86-0.98) 0.011 0.90 (0.79-1.01) 0.059 0.95 (0.86-1.04) 0.18 
rs1800470 TGF Shu et al. [6] Co-dominance A 0.61 0.95 (0.91-0.99) 0.030 0.96 (0.88-1.04) 0.20 0.95 (0.88-1.02) 0.12 
rs3775775 SULT1E1 Choi et al. [46] Dominance G 0.09 1.08 (1.00-1.16) 0.046 1.17 (1.03-1.31) 0.02 1.06 (0.95-1.17) 0.18 
rs700519 CYP19A1 Long et al. [54] Dominance A 0.03 1.10 (0.98-1.22) 0.093 1.03 (0.83-1.23) 0.40 1.30 (1.10-1.50) 0.0050
rs731236 VDR Perna et al. [65] Co-dominance G 0.39 1.04 (1.00-1.08) 0.056 1.03 (0.95-1.11) 0.28 1.09 (1.02-1.16) 0.017
rs12900137 CYP19A1 Long et al. [54] Dominance C 0.05 1.01 (0.91-1.11) 0.47 0.94 (0.78-1.10) 0.70 1.18 (1.02-1.34) 0.032
rs10477313 PPP2R2B Jamshidi et al. [34] Dominance T 0.12 0.94 (0.87- 1.01) 0.08 0.92 (0.79-1.05) 0.15 0.88 (0.77-0.99) 0.035
rs2333227 MPO Ambrosone et al. [44] Dominance T 0.21 1.03 (0.97-1.09) 0.20 0.95 (0.87-1.03) 0.78 1.09 (1.01-1.17) 0.036
rs1902586 CYP19A1 Long et al. [54] Dominance A 0.05 1.01 (0.91-1.11) 0.44 0.99 (0.83-1.15) 0.54 1.16 (1.01-1.31) 0.041
rs28566535 CYP19A1 Long et al. [54] Dominance C 0.05 1.00 (0.90-1.10) 0.51 0.97 (0.81-1.13) 0.60 1.15 (1.00-1.30) 0.046
Hazard ratios are for breast cancer specific survival using a Cox proportional hazards model corrected for principal components. 
Hazard ratios, confidence intervals and p-values are from a co-dominant model. 
P-values refer to a one-sided test of association in the direction indicated in bold in the 90% CI of the HR. 
P-values in bold indicate results that are nominally significant (P<0.05). 
Discussion 
There have been few studies focussed on the replication of sub-genome-wide significant 
associations identified previously. Previous replication studies have focussed on reporting the 
SNPs with the strongest evidence of association. We have found some evidence to support 
previously reported associations between common germline genetic variants and breast 
cancer prognosis. However, the moderate evidence for some variants provides a rationale for 
continued research efforts to identify such variants. Significant variants were for the most 
part candidates in cancer-related genes as is shown in Table 1. Despite the larger sample size 
and therefore increased power to detect true associations with prognosis in comparison to 
previous studies, a possible reason for associations failing to reach genome-wide significance 
may still be limited power. Figure 2a illustrates that for our analysis with 2,900 survival 
events from 37,954 cases, there is limited power to detect associations at stringent 
significance levels for modest effect sizes based on a variant with a 0.3 minor allele 
frequency. Figure 2b shows that almost five times as many events would be needed to detect 
with 80 per cent power at p-value < 10−8 an allele with a minor allele frequency of 0.3 that 
confers a hazard ratio of 1.1. 
Figure 2 Power(%) to detect true associations with survival-time across a range of minor 
allele frequencies and numbers of events. a. Power(%) to detect true associations with 
survival-time over a range of effect sizes at increasing orders of significance given a minor 
allele frequency of 0.3 and 2,900 events. We used an imputation r2 = 0.8 to account for 
suboptimal imputation. b. Power(%) to detect true associations with survival-time for 
increasing numbers of events, at increasing orders of significance, given a minor allele 
frequency of 0.3 and an effect size of 1.1. We used an imputation r2 = 0.8 to account for 
suboptimal imputation. 
In a two-sided test, five of the previously reported associations with prognosis were 
significantly associated with breast cancer specific survival in the GWAS meta-analysis but 
had discordant directions of effect to the original results. These discrepancies may be caused 
by differing ethnicity between the sample populations [20] as the meta-analysis is specific to 
patients with European ancestry whereas the five original studies consider non-European 
populations [6,21-23]. On the other hand they may also represent false positive associations 
in both discovery and replication data. 
Many previously published studies used a dominance model to evaluate associations. We 
only used a co-dominant model to detect association in the GWAS. This is justified because 
thousands of common variants [24] associated with a range of diseases have been identified 
using a co-dominant model with little or no evidence for dominance. It seems unlikely that 
breast cancer survival would differ substantially from other phenotypes in any true, 
underlying genetic model. Where the true underlying model is co-dominant this approach 
will maximise statistical power. While it is possible, that some variants may be truly 
associated under a dominance model, e.g. through loss of heterozygosity of the specific 
germline variant in the tumour, we would still have reasonable power to detect such an 
association with the large sample size of the GWAS under a co-dominant model. 
A further way to increase power to detect robust associations with prognosis is to reduce the 
level of heterogeneity in the phenotype. Studies focussing on identifying subtype specific 
associations will have increased power to detect variants associated with a particular subtype 
than an analysis on all patients will have. In particular, studies considering disease subtypes, 
eg. ER negative disease, may provide valuable information into the reasons for known 
prognostic differences between subtypes. We identified 7 SNPs associated with ER-positive 
disease. These SNPs were not previously identified in specifically ER positive disease, 
however, our observations may agree with the previously reported results as most breast 
cancers are ER positive. In addition, studies looking at interactions with specific treatments, 
most notably adjuvant chemotherapy, hormonal therapy and adjuvant radiotherapy, may 
further inform targeted treatment of subgroups of patients according to their inherited genetic 
information. Some of the previously reported associations with prognosis were found in 
specific subgroups of patients; however as yet the sizes of these studies are limited. Large 
subtype-specific studies are needed in order to investigate interactions with particular 
subgroups effectively. The generation of sufficiently large studies to deliver strongly 
significant results as well as having good outcome and treatment data to enable powerful 
subtype specific analyses, will only be possible by combining data resources through large-
scale global collaborations. Case–control studies including approximately 100,000 cases are 
now being conducted to identify common variants associated with risk. It seems a realistic 
goal to carry out case-cohort studies of a similar size. Reliable identification of SNPs 
associated with breast cancer prognosis may help to understand the molecular mechanisms of 
tumour progression and metastasis. Ultimately, this may lead to the development of new 
therapeutic targets. Polygenic risk scores based on multiple risk alleles have been shown to 
have potentially useful discrimination [25]. Similar polygenic prognostic scores may improve 
discrimination of prognostic and treatment benefit tools such as PREDICT [26]. 
Conclusions 
We have found limited evidence to support the assertion that germline genetic variation 
influences outcome after a diagnosis of breast cancer. Large studies with detailed clinical and 
follow-up information are needed in order to achieve sufficient statistical power to detect 
associations at stringent significance thresholds. In addition, power can also be increased by 
reducing the level of phenotype heterogeneity which will also provide valuable insights into 
prognostic differences between subgroups. 
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